Relevium Technologies (TSXV:RLV; OTCQB:RLLVF) unveiled its two first cannabis brands, LeefyLyfe and Biocannabix.

As quoted in the press release:

LeefyLyfe and Biocannabix brands are part of the wholly owned Biocannabix Health Corporation (the “Subsidiary” or “BHC”).


  • Biocannabix® will target the Canadian market pursuant to ACMPR regulations
  • LeefyLyfe® will target CBD sales outside of Canada in full compliance with local legal and regulatory framework
  • All resources being pooled to fast track the company’s positioning in the cannabis space

Aurelio Useche, CEO of  Relevium stated: “We believe the organizations that build credible, trusted and recognizable brands in the CBD market will be the winners in this already fragmented space. At RLV, we are leveraging our current branding and online abilities in combination with all the resources at our disposal internally and externally to position the Company in the consumer products cannabis space.” Mr. Useche continued: “From formulation to branding and e-retail, we will be able to monetize CBD and CBG based consumer products outside of the Canadian market while the application for an ACMPR license for Canada is being worked on. We believe that this approach provides the best balance of short and mid-term ROI and an ideal risk ratio.”

Click here to read the full press release.


Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less